Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1629
This examiner grants 0% of resolved cases
Examiner Christopher Evan Redwood works in Tech Center 1600 and Art Unit 1629. The examiner has 2 resolved cases. The allowance rate and the interview lift are both 0.0%. These 0.0% metrics serve as the baseline for the examiner's current history. Practitioners should note that the 2 resolved cases represent a small sample size for Art Unit 1629. The data indicates that no cases in this small set have reached allowance or benefited from an interview.
The lack of successful outcomes is based on the same 2 resolved cases. This suggests that interviews have not yet resulted in a measurable increase in the probability of success for this examiner. Practitioners may need to monitor future case resolutions to see if these figures change as the examiner's experience grows. The current data provides a narrow window into the examiner's tendencies.
The median days to allowance is 1095. This 1095-day figure is the median time for cases that reach a grant. Even with the initial results, the 1095-day metric is provided as a reference for pendency. Applicants should consider the 1095 median days to allowance alongside the 2 resolved cases when planning their strategy. These are the primary data points available for this examiner.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18682505 | 2,2-DIFLUORO-5H-[1,3]DIOXOLO[4,5-F]ISOINDOL-7-ONE DERIVATIVES AS PESTICIDES | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18307522 | Methods of Treating Cystic Fibrosis | Non-Final OA | The Trustees of Dartmouth College |
| 18666911 | COMBINATION TREATMENT AND/OR PREVENTION OF CARDIAC DISEASES IN NON-HUMAN MAMMALS COMPRISING ONE OR MORE SGLT-2 INHIBITORS AND PIMOBENDAN AND/OR TELMISARTAN | Non-Final OA | BOEHRINGER INGELHEIM VETMEDICA GMBH |
| 17923891 | METHODS FOR INDUCING BILE ACID SULFOTRANSFERASE SULT2A FOR TREATING METABOLIC DISORDERS | Final Rejection | The Brigham and Women's Hospital, Inc. |
| 18698968 | ALDH Inhibitors to Promote Immune Cell Expansion | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 18232970 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | Final Rejection | Incyte Corporation |
| 18843373 | GPR120 AGONISTS FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE | Non-Final OA | Dompe' Farmaceutici SPA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy